MDCC Molecular Devices (MM)

SUNNYVALE, Calif., April 3 /PRNewswire-FirstCall/ -- Molecular Devices Corporation (NASDAQ:MDCC) today announced the introduction of the SpectraMax(R) M5e multi-detection microplate reader, an extension of the popular five-mode SpectraMax M5 system. The tunable SpectraMax M5e is a monochromator-based reader developed in collaboration with Cisbio international (Bagnols-sur-Ceze, France) and is certified to run HTRF(R) assays. The new system will allow life sciences and drug discovery researchers to increase their productivity by providing them with greater flexibility when using the TRF detection mode. The SpectraMax M5e will debut today at the American Association for Cancer Research Annual Meeting in Washington, D.C. Commenting on the launch, Christopher Silva, Director of Life Sciences Marketing at Molecular Devices, stated, "The HTRF(R) assay platform has given researchers an alternative set of kinase and GPCR assays, in addition to traditional radioactive methods. These new, pre-formulated assays are amenable to a wide variety of assay conditions and provide results within hours. Our customers can now more easily optimize and run HTRF(R) assays on the multiple-mode SpectraMax M5e without the need for a dedicated, filter-based reader." With the SpectraMax M5e, users can choose any wavelength between 250 nm and 850 nm and, using its flexible instrument setup options, select the best-suited parameters for their assays. Like the SpectraMax M5 system, the SpectraMax M5e has primary applications for fluorescence, Time-Resolved Fluorescence, Fluorescence Polarization, absorbance, and luminescence assays. Endpoint, kinetic, spectrum, multi-wavelength, and well-area scanning reading methods can be used to run cell viability and proliferation, kinase, reporter gene, ELISA, nucleic acid and protein quantification, and enzymatic assays. SpectraMax M5e uses Molecular Devices' SoftMax(R) Pro GxP software, the industry-leading data acquisition and analysis software with complete GxP and FDA 21 CFR Part 11 compliance validation tools. About Molecular Devices Corporation Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Molecular Devices' systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and parallel chemistry to facilitate the high-throughput and cost-effective identification and evaluation of drug candidates. Molecular Devices' solutions are based on its advanced core technologies that integrate its expertise in engineering, molecular and cell biology and chemistry. Molecular Devices enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs. About Cisbio international Cisbio international is a global developer of technologies that are used in assay development and drug screening procedures to enhance drug discovery. Cisbio pioneered the field of homogenous fluorescence methodologies via its proprietary technology, HTRF(R), a highly sensitive, robust technology for the detection of molecular interactions of proteins in vitro and widely used by the pharmaceutical industry for the high throughput screening stage of drug development. With its HTRF(R) technology, Cisbio offers a comprehensive technological platform for G-Protein Coupled Receptor (GPCR) screening and kinase screening to customers worldwide. Cisbio also produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies, as well as contract research organizations (CROs). Cisbio international has facilities in France, Bedford, Massachusetts (USA), and Japan. For more information about Cisbio international and HTRF(R), log onto http://www.htrf-assays.com/. Safe Harbor Statement This press release contains "forward-looking" statements, including statements related to the prospects for or potential customer use of the SpectraMax(R) M5e. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Molecular Devices Corporation to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of new products and commercial acceptance, and other risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2005. Molecular Devices Corporation does not undertake any obligation to update forward-looking statements. DATASOURCE: Molecular Devices Corporation CONTACT: Tim Harkness of Molecular Devices Corporation, +1-408-747-3533 Web site: http://www.moleculardevices.com/ http://www.htrf-assays.com/

Copyright